Akeso Biopharma, a Chinese biotech company specialized in innovative antibody drugs, announced on Monday the completion of a $150 million Series D round of financing led by China-focused private equity firm Loyal Valley Capital (LVC) and Hong Kong-listed Sino Biopharm.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
